GlassScriptPhysician profile
Timothy L Beechnau
NPI 1083619936
$2,286.99
in general payments reported to CMS, 2019-2025
21 companies · $663 in 2025
The $663 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $832 · 2020: $150 · 2022: $54.02 · 2023: $195 · 2024: $393 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,250.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $402.18 | 2019-2025 | Ozempic, Rybelsus, Saxenda |
| Pfizer INC. | $316.65 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $276.03 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $238.48 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $215.32 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $110.39 | 2022-2025 | Qulipta |
| Astellas Pharma US INC | $97.90 | 2023-2024 | Veozah |
| Teva Pharmaceuticals USA, INC. | $97.02 | 2020-2025 | Ajovy |
| Novartis Pharmaceuticals Corporation | $75.52 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70.76 | 2019 | |
| Amgen INC. | $69.96 | 2019-2024 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $59.53 | 2024-2025 | Gardasil 9, Vaxneuvance, Rotateq |
| E.R. Squibb & Sons, L.L.C. | $57.96 | 2019-2023 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.60 | 2019 | |
| Amarin Pharma, INC. | $34.36 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $29.84 | 2019-2023 | |
| Shire North American Group INC | $24.50 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $22.06 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.35 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $17.47 | 2025 | Zoryve |
| Exact Sciences Corporation | $16.11 | 2025 | The Cologuard Plus Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Beechnau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.